{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T14:17:20Z","timestamp":1782137840765,"version":"3.54.5"},"reference-count":39,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,6,1]]},"abstract":"<jats:p>Objective. Greater use of invasive procedures and aggressive antimicrobial therapy predispose extremely low birth weight (ELBW) infants to systemic fungal sepsis. Despite its adverse effects (including renal and electrolyte disturbances), amphotericin B (amphoB) remains the preferred drug for fungal therapy. Multiple studies have indicated that sodium loading may prevent renal toxicity among animals and human adults. The effects of fluid and electrolyte management on amphoB-induced nephrotoxicity among ELBW infants have not been evaluated extensively. The purpose of this study was to examine the effects of fluid and electrolyte management on amphoB-induced nephrotoxicity among ELBW infants.<\/jats:p><jats:p>Design\/Methods. The medical records were reviewed for all ELBW infants (birth weights of \u22641250 g) who developed systemic fungal sepsis, requiring amphoB therapy, between January 1992 and December 2000. Demographic, clinical, and laboratory data were collected from the medical records for each patient.<\/jats:p><jats:p>Results. Fungal sepsis requiring amphoB treatment developed for 4.4% of ELBW infants (25 of 573 infants), with a gestational age of 25 \u00b1 1 weeks and a birth weight of 738 \u00b1 37 g, at a postnatal age of 16 \u00b1 2 days. Renal compromise, as manifested by low urine output and high creatinine levels, occurred for 44% of those infants (11 of 25 infants). There was no difference between the infants who developed renal compromise (renal compromise group [RCG], n = 11) and those who did not (no\u2013renal-compromise group [NCG], n = 14) with respect to birth weight, gestational age, and risk factors predisposing the infants to fungal sepsis. The RCG demonstrated a decrease in urine output by 3.4 \u00b1 2 days and an increase in serum creatinine levels by 3.9 \u00b1 2 days after the initiation of amphoB therapy. Infants in the RCG had a significantly higher incidence of hyponatremia, compared with infants in the NCG (7 of 11 infants vs 0 of 14 infants), with no significant difference in the incidences of hypokalemia (2 of 11 infants vs 0 of 14 infants). Infants in the RCG, compared with infants in the NCG, had significantly lower mean daily sodium intakes in the 4 days before the initiation of amphoB therapy (2.6\u20132.9 mEq\/kg per day vs 4.2\u20134.7 mEq\/kg per day) and in the first 4 days of amphoB treatment (2.7\u20133.1 mEq\/kg per day vs 4.5\u20135.6 mEq\/kg per day). Mean daily sodium intakes were not statistically significantly different between the 2 groups between day 5 and day 10 of amphoB therapy. Infants in the RCG tended to have lower mean daily potassium intakes in the 4 days before the initiation of amphoB therapy and during the first 4 days of amphoB therapy. Subsequently, the mean daily potassium intakes remained not statistically significantly different between the groups. Mean daily fluid intakes were not different between the groups.<\/jats:p><jats:p>Conclusions. Conventional amphoB combined with adequate hydration and higher sodium intakes of &amp;gt;4 mEq\/kg per day may provide effective protection against amphoB-induced nephrotoxicity among ELBW infants. Our data confirm the published results of animal and human adult studies and suggest that higher sodium intakes may prevent renal compromise during amphoB therapy among ELBW infants.<\/jats:p>","DOI":"10.1542\/peds.113.6.e608","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:53:04Z","timestamp":1092444784000},"page":"e608-e616","source":"Crossref","is-referenced-by-count":47,"title":["Effects of Fluid and Electrolyte Management on Amphotericin B-Induced Nephrotoxicity Among Extremely Low Birth Weight Infants"],"prefix":"10.1542","volume":"113","author":[{"given":"Bernd","family":"Holler","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Human Development, College of Human Medicine"},{"name":"Division of Neonatology, Sparrow Regional Children\u2019s Center, Lansing, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said A.","family":"Omar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Human Development, College of Human Medicine"},{"name":"Division of Neonatology, Sparrow Regional Children\u2019s Center, Lansing, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maged D.","family":"Farid","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Human Development, College of Human Medicine"},{"name":"Division of Neonatology, Sparrow Regional Children\u2019s Center, Lansing, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jevitz","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Human Development, College of Human Medicine"},{"name":"Departments of Microbiology and Molecular Genetics"},{"name":"Pediatrics, College of Osteopathic Medicine, Michigan State University, East Lansing, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,6,1]]},"reference":[{"key":"2021121006300511700_R1","doi-asserted-by":"crossref","unstructured":"Richardson DK, Gray JE, Gortmaker SL, Goldmann DA, Pursley DM, McCormick MC. Declining severity adjusted mortality: evidence of improving neonatal intensive care. Pediatrics.1998;102:893\u2013899","DOI":"10.1542\/peds.102.4.893"},{"key":"2021121006300511700_R2","doi-asserted-by":"crossref","unstructured":"Noyola DE, Fernandez M, Moylett EH, Baker CJ. Ophthalmologic, visceral, and cardiac involvement in neonates with candidemia. Clin Infect Dis.2001;3:1018\u20131023","DOI":"10.1086\/319601"},{"key":"2021121006300511700_R3","doi-asserted-by":"crossref","unstructured":"Fernandez M, Moylett EH, Noyola DE, Baker CJ. Candidal meningitis in neonates: a 10-year review. Clin Infect Dis.2002;31:458\u2013463","DOI":"10.1086\/313973"},{"key":"2021121006300511700_R4","doi-asserted-by":"crossref","unstructured":"Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics.2002;110:285\u2013291","DOI":"10.1542\/peds.110.2.285"},{"key":"2021121006300511700_R5","doi-asserted-by":"crossref","unstructured":"Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. Pediatr Infect Dis J.1998;17:504\u2013508","DOI":"10.1097\/00006454-199806000-00014"},{"key":"2021121006300511700_R6","doi-asserted-by":"crossref","unstructured":"Karlowicz MG, Hashimoto LN, Kelly RE, Buescher ES. Should central venous catheters be removed as soon as candidemia is detected in neonates?Pediatrics.2000;106(5). Available at: www.pediatrics.org\/cgi\/content\/full\/106\/5\/e63","DOI":"10.1542\/peds.106.5.e63"},{"key":"2021121006300511700_R7","doi-asserted-by":"crossref","unstructured":"Saxen H, Virtanen M, Carlson P, et al. Neonatal Candida parapsilosis outbreak with a high case fatality rate. Pediatr Infect Dis J.1995;14:776\u2013781","DOI":"10.1097\/00006454-199509000-00009"},{"key":"2021121006300511700_R8","doi-asserted-by":"crossref","unstructured":"Faix RG. Invasive neonatal candidiasis: comparison of albicans and parapsilosis infection. Pediatr Infect Dis J.1992;11:88\u201393","DOI":"10.1097\/00006454-199202000-00006"},{"key":"2021121006300511700_R9","doi-asserted-by":"crossref","unstructured":"Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low-birth-weight infants: clinical manifestations and epidemiology. Pediatrics.1984;73:144\u2013152","DOI":"10.1542\/peds.73.2.144"},{"key":"2021121006300511700_R10","doi-asserted-by":"crossref","unstructured":"Friedman S, Richardson SE, Jacobs SE, O\u2019Brien K. Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J.2000;19:499\u2013504","DOI":"10.1097\/00006454-200006000-00002"},{"key":"2021121006300511700_R11","doi-asserted-by":"crossref","unstructured":"Faix RG, Kovarik SM, Shaw TR, Johnson RV. Mucocutaneous and invasive candidiasis among very low-birth-weight (&lt;1500 grams) infants in intensive care nurseries: a prospective study. Pediatrics.1989;83:101\u2013107","DOI":"10.1542\/peds.83.1.101"},{"key":"2021121006300511700_R12","doi-asserted-by":"crossref","unstructured":"Rowen JL, Tate JM, Neonatal Candidiasis Study Group. Management of neonatal candidiasis. Pediatr Infect Dis J.1998;17:1007\u20131011","DOI":"10.1097\/00006454-199811000-00008"},{"key":"2021121006300511700_R13","doi-asserted-by":"crossref","unstructured":"Baley JE, Meyers C, Kliegman RM, et al. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr.1990;116:791\u2013797","DOI":"10.1016\/S0022-3476(05)82674-5"},{"key":"2021121006300511700_R14","doi-asserted-by":"crossref","unstructured":"Fanos V, Cataldi L. Amphotericin B-induced nephrotoxicity: a review. J Chemother.2000;12:463\u2013470","DOI":"10.1179\/joc.2000.12.6.463"},{"key":"2021121006300511700_R15","doi-asserted-by":"crossref","unstructured":"Stein RS, Alexander JA. Sodium protects against nephrotoxicity in patients receiving amphotericin B. Am J Med Sci.1989;298:299\u2013304","DOI":"10.1097\/00000441-198911000-00004"},{"key":"2021121006300511700_R16","unstructured":"Heideman H. Prevention of amphotericin B nephrotoxicity: the effect of salt loading and flucytocine. Mycoses.31(suppl 2):39\u201344,1988"},{"key":"2021121006300511700_R17","doi-asserted-by":"crossref","unstructured":"Ohnishi A, Ohnishi T, Stevenhead W, et al. Sodium status influences chronic amphotericin B nephrotoxicity in rats. Antimicrob. Agents Chemother.33:1222\u20131227,1989","DOI":"10.1128\/AAC.33.8.1222"},{"key":"2021121006300511700_R18","doi-asserted-by":"crossref","unstructured":"Gardner ML, Godley PJ, Wasan SM. Sodium loading treatment for amphotericin B-induced nephrotoxicity. DICP.1990;24:940\u2013946","DOI":"10.1177\/106002809002401006"},{"key":"2021121006300511700_R19","doi-asserted-by":"crossref","unstructured":"Sabra R, Branch RA. Mechanisms of amphotericin B-induced decrease in glomerular filtration rate in rats. Antimicrob Agents Chemother.35:2509\u20132514,1991","DOI":"10.1128\/AAC.35.12.2509"},{"key":"2021121006300511700_R20","doi-asserted-by":"crossref","unstructured":"Llanos A, Cieza J, Bernado J, et al. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int.1991;40:302\u2013308","DOI":"10.1038\/ki.1991.214"},{"key":"2021121006300511700_R21","unstructured":"Anderson CM. Sodium chloride treatment of amphotericin B nephrotoxicity: standard of care?West J Med.1995;162:313\u2013317"},{"key":"2021121006300511700_R22","doi-asserted-by":"crossref","unstructured":"Bernardo JF, Murakami S, Branch RA, Sabra R. Potassium depletion potentiates amphotericin B-induced toxicity to renal tubules. Nephron.1995;70:235\u2013241","DOI":"10.1159\/000188590"},{"key":"2021121006300511700_R23","doi-asserted-by":"crossref","unstructured":"Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis.2002;186:379\u2013388","DOI":"10.1086\/341662"},{"key":"2021121006300511700_R24","unstructured":"Miano-Mason TM. Mechanisms and management of amphotericin B-induced nephrotoxicity. Cancer Pract.1997;5:176\u2013181"},{"key":"2021121006300511700_R25","doi-asserted-by":"crossref","unstructured":"Arishi HA, Frayha HH, Kalloghlian A, Alaiyan SA. Liposomal amphotericin B in neonates with invasive candidiasis. Am J Perinatol.1998;15:643\u2013648","DOI":"10.1055\/s-2007-994083"},{"key":"2021121006300511700_R26","doi-asserted-by":"crossref","unstructured":"Weitkamp JH, Poets CF, Sievers R, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection.1998;26:11\u201315","DOI":"10.1007\/BF02768745"},{"key":"2021121006300511700_R27","doi-asserted-by":"crossref","unstructured":"Walsh TJ, Seibel NL, Arndt C, et al. Amphotericin B lipid complex in pediatric patients with invasive fungal infections. Pediatr Infect Dis J.1999;18:702\u2013708","DOI":"10.1097\/00006454-199908000-00010"},{"key":"2021121006300511700_R28","doi-asserted-by":"crossref","unstructured":"Scarcella A, Pasquariello MB, Giugliano B, Vendemmia M, De Lucia A. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J.1998;17:146\u2013148","DOI":"10.1097\/00006454-199802000-00013"},{"key":"2021121006300511700_R29","doi-asserted-by":"crossref","unstructured":"Adler-Shohet F, Waskin H, Lieberman JM. Amphotericin B lipid complex for neonatal invasive candidiasis. Arch Dis Child Fetal Neonatal Ed.2001;84:F131\u2013F133","DOI":"10.1136\/fn.84.2.F131"},{"key":"2021121006300511700_R30","doi-asserted-by":"crossref","unstructured":"Friedlich PS, Steinberg I, Fujitani A, deLemos RA. Renal tolerance with the use of Intralipid-amphotericin B in low birth weight neonates. Am J Perinatol.1997;14:377\u2013383","DOI":"10.1055\/s-2007-994164"},{"key":"2021121006300511700_R31","doi-asserted-by":"crossref","unstructured":"Butler KM, Rench MA, Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J.1990;9:51\u201356","DOI":"10.1097\/00006454-199001000-00012"},{"key":"2021121006300511700_R32","doi-asserted-by":"crossref","unstructured":"Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis.1999;29:1402\u20131407","DOI":"10.1086\/313498"},{"key":"2021121006300511700_R33","unstructured":"White MH, Bowden RA, Sandler ES, et al. Amphotericin B colloidal dispersion vs amphotericin B as therapy for invasive aspergillosis. Clin Infect Dis.1997;24:635\u2013642"},{"key":"2021121006300511700_R34","doi-asserted-by":"crossref","unstructured":"Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med.1999;340:764\u2013771","DOI":"10.1056\/NEJM199903113401004"},{"key":"2021121006300511700_R35","doi-asserted-by":"crossref","unstructured":"Prentice HG, Hann IM, Herbrecht R, et al. A randomized comparison of liposomal vs conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol.1997;98:711\u2013718","DOI":"10.1046\/j.1365-2141.1997.2473063.x"},{"key":"2021121006300511700_R36","unstructured":"Gerkens JF, Branch RA. The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity. J Pharmacol Exp Ther.1980;214:306\u2013311"},{"key":"2021121006300511700_R37","doi-asserted-by":"crossref","unstructured":"Sawaya BP, Weihprecht H, Campell WR. Direct vasoconstriction as a possible cause for amphotericin B-induced nephrotoxicity in rats. J Clin Invest.1991;87:2097\u20132107","DOI":"10.1172\/JCI115240"},{"key":"2021121006300511700_R38","doi-asserted-by":"crossref","unstructured":"Heideman HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med.1983;75:476\u2013481","DOI":"10.1016\/0002-9343(83)90353-4"},{"key":"2021121006300511700_R39","doi-asserted-by":"crossref","unstructured":"Thompson JR, Simonsen R, Spindler MA, Southern PM, Cronin RE. Protective effect of KCl loading in gentamicin nephrotoxicity. Am J Kidney Dis.1990;15:583\u2013591","DOI":"10.1016\/S0272-6386(12)80530-0"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/113\/6\/e608\/1004190\/zpe0060400e608.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/113\/6\/e608\/1004190\/zpe0060400e608.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T05:40:15Z","timestamp":1682746815000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/113\/6\/e608\/64305\/Effects-of-Fluid-and-Electrolyte-Management-on"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,1]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2004,6,1]]},"published-print":{"date-parts":[[2004,6,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.113.6.e608","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,1]]}}}